Gossamer Bio (GOSS) Short-term Investments (2018 - 2026)

Gossamer Bio's Short-term Investments history runs 9 years deep, the most recent figure standing at $58.2 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 74.58% year-over-year to $58.2 million; the TTM figure through Mar 2026 stood at $58.2 million (down 74.58% YoY), while the FY2025 annual figure was $99.2 million, down 60.07% from the prior year.
• Short-term Investments for Q1 2026 stood at $58.2 million, down from $99.2 million in the prior quarter.
• The five-year high for Short-term Investments was $298.6 million in Q3 2024, with the low at $64000.0 in Q1 2022.
• The 5-year median for Short-term Investments is $179.0 million (2025), against an average of $175.5 million.
• Peak annual rise in Short-term Investments reached 224439.06% in 2022, while the deepest fall reached 99.53% in 2022.
• Gossamer Bio's Short-term Investments stood at $143.7 million in 2022, then soared by 83.93% to $264.3 million in 2023, then retreated by 6.0% to $248.4 million in 2024, then sank by 60.07% to $99.2 million in 2025, then tumbled by 41.34% to $58.2 million in 2026.
• Business Quant data shows GOSS's Short-term Investments at $58.2 million in Q1 2026, $99.2 million in Q4 2025, and $171.3 million in Q3 2025.